Sittingbourne, United Kingdom

C John Harris

USPTO Granted Patents = 5 


Average Co-Inventor Count = 14.9

ph-index = 5

Forward Citations = 99(Granted Patents)


Company Filing History:


Years Active: 2005-2011

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: **The Innovative Mind of C John Harris: Advancements in HDAC Inhibition**

Introduction

C John Harris, an accomplished inventor based in Sittingbourne, GB, has made significant contributions to the field of pharmaceutical sciences. With a notable record of five patents to his name, he has focused his research on novel carbamic acid compounds, particularly their application as inhibitors of histone deacetylase (HDAC) activity. His work promises to impact therapeutic strategies for various proliferative conditions, including cancer and psoriasis.

Latest Patents

Among C John Harris's latest patents are innovative carbamic acid compounds that comprise an amide linkage serving as HDAC inhibitors. These compounds feature a chemical formula that incorporates aryl groups and unique amide linkages, which are critical in inhibiting HDAC activity. The invention emphasizes the development of pharmaceutical compositions that utilize these compounds, demonstrating their efficacy in both in vitro and in vivo applications to address conditions like cancer and psoriasis.

Career Highlights

Harris has dedicated a substantial part of his career to the research and development of pharmaceutical solutions. His work at Topotarget UK Limited underlines his commitment to advancing medical treatments through innovative approaches. The significance of his research lies not only in the results of his patents but also in their potential therapeutic applications, paving the way for more effective treatment options for patients suffering from critical health issues.

Collaborations

Throughout his career, C John Harris has collaborated with esteemed colleagues such as Clare J Watkins and Maria Rosario Romero-Martin. Together, they have contributed to the scientific community’s understanding of HDAC inhibitors, working collectively to enhance the efficacy of therapeutic compounds in clinical settings. Their collaboration highlights the importance of teamwork in the advancement of scientific research and innovation.

Conclusion

C John Harris stands out as a leading figure in the realm of pharmaceutical innovations with his pioneering contributions to HDAC inhibitors. His extensive patent portfolio and collaborative efforts reflect a passionate commitment to improving medical treatments. As research continues to evolve, the work of inventors like Harris will undoubtedly remain central to the advancement of healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…